Combined use of carbon nanotubes and ionic liquid to improve the determination of antidepressants in urine samples by liquid chromatography

被引:0
作者
Marta Cruz-Vera
Rafael Lucena
Soledad Cárdenas
Miguel Valcárcel
机构
[1] University of Cordoba,Department of Analytical Chemistry, Marie Curie Building(Annex), Campus de Rabanales
来源
Analytical and Bioanalytical Chemistry | 2008年 / 391卷
关键词
Multiwalled carbon nanotubes; Ionic liquid; Solid-phase extraction; Liquid chromatography; Antidepressants; Urine samples;
D O I
暂无
中图分类号
学科分类号
摘要
Antidepressants are widely used for the treatment of psychiatric disorders and therefore their monitoring in biological fluids is quite important taking into account that they can produce dangerous biochemical imbalances in toxic doses. A method for the determination of antidepressants in urine samples is presented using solid-phase extraction (SPE) and high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection. Home-made cartridges containing 30 mg multiwall carbon nanotubes are employed for isolation of the analytes from the sample, allowing also the preconcentration of the analytes prior to the HPLC analysis. Chromatographic separation was achieved in a reversed-phase C8 column using the ionic liquid 1-butyl-3-methylimidazolium trifluoromethanesulfonate as silanol activity suppressor, which enhances peak symmetry and chromatographic resolution. Limits of detection were 12.3 ng mL−1 for trazodone and 90.1 ng mL−1 for fluoxetine. The repeatability of the proposed method expressed as RSD (n = 11) varied between 3.4% (fluoxetine) and 5.0% (desipramine and mianserine). Thus, the method is suitable for the therapeutic monitoring of antidepressants in urine samples.
引用
收藏
页码:1139 / 1145
页数:6
相关论文
共 119 条
[1]  
Bridge JA(2007)undefined J Am Med Assoc 297 1683-1696
[2]  
Iyengar S(2006)undefined J Chromatogr B 843 100-113
[3]  
Salary CB(2003)undefined J Anal Toxicol 27 353-358
[4]  
Barbe RP(2004)undefined Chromatographia 59 161-165
[5]  
Birmaher B(2004)undefined Forensic Sci Int 141 115-120
[6]  
Pincus HA(2004)undefined Ther Drug Monit 26 47-52
[7]  
Ren L(2004)undefined J Chromatogr B 801 213-220
[8]  
Brent DA(2005)undefined Int J Immunopathol Pharmacol 18 567-573
[9]  
Kirchherr H(2006)undefined Rapid Commun Mass Spectrom 20 1637-1642
[10]  
Kuehn-Velten WN(2004)undefined J Chromatogr B 806 205-219